Efforts to Improve Quality of Migraine Medical Care
This Pfizer and Japanese Headache Society grant funds projects in Japan that use education and behavioral science to improve early diagnosis and care of migraine through sustainable, evidence-based interventions.
Funder: Pfizer Inc.
Due Dates: June 15, 2026 (submission deadline, full application) | June 30, 2026 (extended submission deadline, full application)
Funding Amounts: Up to 1.2 million JPY per project (approx. $7,500 USD); project duration up to 2 years
Summary: Supports projects in Japan to improve migraine care through behavioral change, education, and early diagnosis targeting healthcare professionals and the broader community.
Key Information: Only organizations (not individuals) may apply; projects must not be clinical research or evaluate therapeutic/diagnostic agents.
Description
This grant program, sponsored by Pfizer and the Japanese Headache Society, seeks to fund projects that improve the quality of migraine medical care in Japan. The focus is on behavioral change and educational interventions that facilitate early diagnosis and appropriate treatment for migraine sufferers. Eligible projects may include mechanisms to encourage patients to seek medical care, enhance collaboration between expert and non-expert doctors, improve disease understanding among children and adolescents, and provide comprehensive migraine education to school and occupational health professionals. The program aims to translate existing knowledge into practice to ensure timely clinical care and informed management for migraine patients, with a strong emphasis on sustainable, measurable improvements in healthcare delivery.
